Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scribe TherapeuticsSCTX -13.40%8 EV-to-EBITDA is 0.00 as of Jul. 26, 2026. GuruFocus rates SCTX with a GF Score™ of 8/100. Among 404 Biotechnology companies, Scribe Therapeutics ranks worse than 247524.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scribe Therapeutics's enterprise value is $0.00 Mil.
Scribe Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-15.75 Mil. Therefore, Scribe Therapeutics's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Scribe Therapeutics's EV-to-EBITDA or its related term are showing as below:
SCTX's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 11.82 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scribe Therapeutics's PE Ratio (TTM) for today is calculated as:
Scribe Therapeutics's share price for today is $22.00.
Scribe Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Scribe Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scribe Therapeutics EV-to-EBITDA Chart
Scribe Therapeutics Annual Data
Trend
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
Scribe Therapeutics Quarterly Data
Dec24
Mar25
Dec25
Mar26
EV-to-EBITDA
0.00
0.00
0.00
0.00
SCTX vs : EV-to-EBITDA Comparison
For the Biotechnology subindustry, Scribe Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scribe Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scribe Therapeutics's EV-to-EBITDA falls into.
Scribe Therapeutics's current Enterprise Value is $0.00 Mil.
Scribe Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scribe Therapeutics (SCTX) has a EV-to-EBITDA of 0.00 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scribe Therapeutics. According to the industry distribution chart, Scribe Therapeutics ranks #999999 out of 404 companies in the Biotechnology industry.
Is Scribe Therapeutics' EV-to-EBITDA too high?
Scribe Therapeutics' current EV-to-EBITDA is 0.00. Based on the distribution chart, Scribe Therapeutics ranks #999999 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' EV-to-EBITDA compare to ?
According to the Biotechnology industry distribution chart, Scribe Therapeutics ranks #999999 out of 404 companies for EV-to-EBITDA. This places Scribe Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 11.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scribe Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scribe Therapeutics's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current EV-to-EBITDA is 0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score
Get the complete analysis for SCTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCTX has been successfully added to your 
